NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$2.20
+0.01 (+0.46%)
Open$2.20
Previous Close$2.19
Day High$2.31
Day Low$2.09
52W High$8.49
52W Low$2.71
Volume—
Avg Volume50.7K
Market Cap230.04M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+467.7% upside
Current
$2.20
$2.20
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,114.20 | +0.64% | 40.9 | 1.03T |
| JNJ | Johnson & Johnson | $240.15 | +0.45% | 26.1 | 549.78B |
| MRK | Merck & Co. Inc. | $121.17 | +1.31% | 31.5 | 281.24B |
| PFE | Pfizer Inc. | $24.09 | -2.55% | 19.2 | 143.68B |
| BMY | Bristol-Myers Squibb Co | $55.53 | +1.52% | 18.5 | 110.27B |
| ZTS | Zoetis Inc | $78.15 | +1.70% | 12.5 | 33.00B |